Documentation of iron stores in patients with myelodysplastic syndrome (MDS) (Measure 68)
If patient has Myelodysplastic syndrome (ICD-9 diagnosis codes: 238.72, 238.73, 238.74, 238.75 AND CPT E/M service codes: 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99244 and 99245), recommend to calculate body’s iron stores before starting treatment with erythropoietin. To be effective erythropoietin requires that adequate iron stores be present due to iron’s importance in red-blood-cell synthesis. Iron deficiency presents a major limitation to the efficacy of erythropoietin therapy.
| DESCRIPTION: Percentage of patients aged 18 years and older with a diagnosis of MDS (myelodysplastic syndrome) who are receiving erythropoietin therapy with documentation of iron stores prior to initiating erythropoietin therapy GUIDELINE: If patient has Myelodysplastic syndrome, recommend to calculate body’s iron stores before starting treatment with erythropoietin. To be effective erythropoietin requires that adequate iron stores be present due to iron’s importance in red-blood-cell synthesis. Iron deficiency presents a major limitation to the efficacy of erythropoietin therapy. |
Reference:
- NCCN Clinical practice guidelines in oncology. Myelodysplastic syndromes. V-2-2008 http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf
- Goldberg H, Lusk E, Moore J, et al: Survey of exposure to genotoxic agents in primary myelodysplastic syndrome: correlation with chromosome patterns and data on patients without hematological disease. Cancer Res 1990 Nov 1; 50(21): 6876-81
- Westbrook, CA, Hsu, WT, Chyna, B, et al. Cytogenetic and molecular diagnosis of chromosome 5 deletions in myelodysplasia. Br J Haematol 2000; 110:847.
- Jacobs, RH,
- Rose, EH, Abels, RI, Nelson, RA, et al. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 1995; 89:831.
0 comments:
Post a Comment